ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS

Cover Page

Cite item

Abstract

Aspergillus is a saprophytic mold and its natural habitat is the soil. It is found worldwide indoors and outdoors in potted soil, compost, freshly cut grasses, decaying vegetation and in sewers. Aspergillus produces a bountiful number of spores and releases 2-3 micron sized spores into the air daily. It grows best at 37-40 °C, which is similar to the temperature in the lungs. These spores will remain airborne for a long period of time. It is estimated that humans inhale hundreds of spores daily. Several fungi other than aspergillus have been known to be implicated. Hence, the term allergic bronchopulmonary mycoses would be more appropriate unless the specific fungus is identified - which could be candida, helminthosporium, curvularia, bipolaris, cladosporium, or others. The review article is focused on the prototype allergic bronchopulmonary aspergillosis, its epidemiology, pathogenesis, diagnosis and treatment. Bronchopulmonary aspergillosis should be considered in patients with poorly controlled asthma despite appropriate routine therapy and environmental control. The need for frequent courses of corticosteroids with temporary improvement should raise the index of suspicion and appropriate evaluation be done. Early recognition and prompt initiation of appropriate corticosteroid treatment regimen would reduce the risk of development or progression of bronchiectasis and lung tissue damage. Regular follow up and monitoring serum total IgE level can predict exacerbations and should prompt corticosteroid treatment. Long term follow-up is important as relapses can occur years of remission.

About the authors

Rashmi D’Mello

Allergy and Immunology Section, Louisiana State University Health Sciences Center

Author for correspondence.
Email: SBahna@LSUHSC.edu
Shreveport, Louisiana, U.S.A

Sasikumar Kilaikode

Pediatric Pulmonary Section, Louisiana State University Health Sciences Center

Email: SBahna@LSUHSC.edu
Shreveport, Louisiana, U.S.A

Sami L. Bahna

Allergy and Immunology Section, Louisiana State University Health Sciences Center

Email: SBahna@LSUHSC.edu
Shreveport, Louisiana, U.S.A

References

  1. Centers for Disease Control and Prevention. Etymologia: Aspergillus. Emerg Infect Dis. 2006;12(3):415.
  2. Lee J. Discovery of Aspergillus as a Human Pathogen. Retrieved January 15, 2019, from http://www.antimicrobe.org/ hisphoto/history/Aspergillus-Human%20Pathogens.asp.
  3. Macartney JN. Pulmonary Aspergillosis: A Review and a Description of Three New Cases. Thorax. 1964;19(4): 287-297.
  4. Hinson KF, Moon AJ, Plummer NS. Broncho-pulmonary aspergillosis; a review and a report of eight new cases. Thorax. 1952;7(4):317-333.
  5. Latgé JP. Aspergillus fumigatus and Aspergillosis. Clin Microbiol Rev.1999; 12(2):310-350.
  6. Knutsen AP, Slavin RG. Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. Clin Dev Immunol. 2011;2011:843763:1-13.
  7. Patterson K, Strek ME. Allergic Bronchopulmonary Aspergillosis. Proc Am Thorac Soc. 2010;7(3):237-44.
  8. Tillie-Leblond I, Tonnel AB. Allergic bronchopulmonary aspergillosis. Allergy. 2005;60(8):1004-1013.
  9. Amitani R, Kawanami R. Interaction of Aspergillus with human respiratory mucosa: a study with organ culture model. Med Mycol. 2009;47 Suppl 1:S127-131.
  10. Kauffman HF, Tomee JF, van der Werf TS, de Monchy JG, Koeter GK. Review of fungus-induced asthmatic reactions. Am J Respir Crit Care Med. 1995;151(6): 2109-2116.
  11. Garcia G, Humbert M, Capel F, et al. Chemokine receptor expression on allergen-specific T cells in asthma and allergic bronchopulmonary aspergillosis. Allergy. 2007; 62(2):170-177.
  12. Miller PW, Hamosh A, Macek M, Jr., et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am J Hum Genet. 1996;59(1):45-51.
  13. Ueki S, Hebisawa A, Kitani M, Asano K, Neves JS. Allergic Bronchopulmonary Aspergillosis-A Luminal Hypereosinophilic Disease With Extracellular Trap Cell Death. Front Immunol. 2018;9(2346):1-9.
  14. Douglass JA, Sandrini A, Holgate ST, O’Hehir RE. (2013). Allergic Bronchopulmonary Aspergillosis and Hypersensitivity Pneumonitis. In: N. Adkinson Jr, B. Bochner, A. Burks, W. Busse, S. Holgate, R. Lemanske, R. O'Hehir (Eds.), Middleton's Allergy Principles and Practice 8th edition: 2-Volume Set. (pp1000-1012). Philadelphia, PA: Elsevier Saunders.
  15. Akuthota P, Weller P. (2017, June 29). Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis - UpToDate. Retrieved January 15, 2019, from https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-allergic-bronchopulmonary-aspergillosis? search=abpa&source=search_result&selectedTitle=1~51&usage_type=default&display_rank=1#H1248738776.
  16. Agarwal R, Maskey D, Aggarwal AN, et al. Diagnostic Performance of Various Tests and Criteria Employed in Allergic Bronchopulmonary Aspergillosis: A Latent Class Analysis. PLoS One. 2013;8(4)e61105:1-7.
  17. Shah A, Panjabi C. Allergic Bronchopulmonary Aspergillosis: A Perplexing Clinical Entity. Allergy Asthma Immunol Res. 2016;8(4):282-297.
  18. Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M, Harris KE. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med. 1977;86(4):405-414.
  19. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2002;110(5):685-692.
  20. Agarwal R, Khan A, Gupta D, Aggarwal AN, Saxena AK, Chakrabarti A. An alternate method of classifying allergic bronchopulmonary aspergillosis based on high-attenuation mucus. PLoS One. 2010;5(12):e15346:1-9.
  21. Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43(8):850-873.
  22. Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2009; 13(8):936-944.
  23. Menzies D, Holmes L, McCumesky G, Prys-Picard C, Niven R. Aspergillus sensitization is associated with airflow limitation and bronchiectasis in severe asthma. Allergy. 2011;66(5):679-685.
  24. Greenberger PA, Patterson R. Allergic bronchopulmonary aspergillosis. Model of bronchopulmonary disease with defined serologic, radiologic, pathologic and clinical findings from asthma to fatal destructive lung disease. Chest. 1987;91(6 Suppl):165s-171s.
  25. Patterson R, Greenberger PA, Halwig JM, Liotta JL, Roberts M. Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med. 1986;146(5):916-918.
  26. Agarwal R, Gupta D, Aggarwal AN, Behera D, Jindal SK. Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India. Chest. 2006;130(2):442-448.
  27. Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183(1):96-128.
  28. Agarwal R, Gupta D, Aggarwal AN, et al. Clinical significance of decline in serum IgE levels in allergic bronchopulmonary aspergillosis. Respir Med. 2010;104(2):204-210.
  29. Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med. 2000;342(11):756-762.
  30. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis. 2003;37(Suppl 3):S225-264.
  31. Patterson TF, Thompson GR, 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60.
  32. Parmar JS, Howell T, Kelly J, Bilton D. Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis. Thorax. 2002;57(8):749-750.
  33. Chishimba L, Niven RM, Cooley J, Denning DW. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. J Asthma. 2012;49(4):423-433.
  34. Tillie-Leblond I, Germaud P, Leroyer C, et al. Allergic bronchopulmonary aspergillosis and omalizumab. Allergy. 2011;66(9):1254-1256.
  35. Knutsen AP, Bush RK, Demain JG, et al. Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol. 2012;129(2):280-291.
  36. Tracy MC, Okorie CUA, Foley EA, Moss RB. Allergic Bronchopulmonary Aspergillosis. J Fungi (Basel). 2016; 2(2)17:1-18.

Copyright (c) 2019 D’Mello R., Kilaikode S., Bahna S.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies